Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | HPGD | P15428 | 4/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.50 |
| ▸ | ATM | Q13315 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | GLA | P06280 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | CASP1 | P29466 | 1/20 | 0.50 |
| ▸ | CASP7 | P55210 | 1/20 | 0.50 |
| ▸ | KDM6B | O15054 | 1/20 | 0.46 |
| ▸ | KDM5C | P41229 | 1/20 | 0.46 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.46 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.46 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.46 |
| ▸ | TPMT | P51580 | 3/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA7 | P43166 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL490266 | 0.89 | KDM4E (0.62) | KDM4EALDH1A1HPGDHSD17B10ATM | |
| SCHEMBL9480687 | 0.87 | KDM4E (0.51) | KDM4EALDH1A1HPGDHSD17B10ATM | |
| SCHEMBL3112544 | 0.86 | KDM4E (0.50) | KDM4EALDH1A1HPGDHSD17B10ATM | |
| SCHEMBL29699657 | 0.83 | KDM4E (0.55) | KDM4EALDH1A1HPGDHSD17B10ATM | |
| SCHEMBL820141 | 0.83 | KDM4E (0.55) | KDM4EALDH1A1HPGDHSD17B10ATM | |
| SCHEMBL27457866 | 0.82 | TPMT (0.44) | KDM4EALDH1A1GAAMAPTTPMT | |
| SCHEMBL19693590 | 0.82 | ATR (0.41) | KDM4EALDH1A1HPGDATMGAA | |
| SCHEMBL1018113 | 0.81 | KDM4E (0.53) | KDM4EALDH1A1HPGDHSD17B10ATM | |
| SCHEMBL293610 | 0.81 | KDM4E (0.53) | KDM4EALDH1A1HPGDHSD17B10ATM | |
| SCHEMBL293611 | 0.81 | KDM4E (0.55) | KDM4EALDH1A1HPGDHSD17B10ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250213685-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2025-07-03 | — | — | US | disclosed |
| US-20250177374-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | ABBVIE INC (US) | 2025-06-05 | — | — | US | disclosed |
| US-20240425517-A1 | NOVEL COMPOUND FOR DEGRADATION OF TARGET PROTEIN OR POLYPEPTIDE BY POLYUBIQUITINATION | PRAZER THERAPEUTICS INC. (KR) | 2024-12-26 | — | — | US | disclosed |
| EP-4450490-A1 | NOVEL COMPOUND FOR DEGRADING TARGET PROTEIN OR POLYPEPTIDE BY USING POLYUBIQUITINATION | Prazer Therapeutics Inc. (KR) | 2024-10-23 | — | — | EP | disclosed |
| US-20240199745-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2024-06-20 | — | — | US | disclosed |
| EP-4364754-A2 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2024-05-08 | — | — | EP | disclosed |
| US-20240058450-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | ABBVIE INC (US) | 2024-02-22 | — | — | US | disclosed |
| CN-109963870-B | anti-B7-H3 antibodies and antibody drug conjugates | 艾伯维公司 | 2023-07-28 | — | — | CN | disclosed |
| CN-116284404-A | anti-B7-H3 antibodies and antibody drug conjugates | 艾伯维公司 | 2023-06-23 | — | — | CN | disclosed |
| WO-2023113457-A1 | NOVEL COMPOUND FOR DEGRADING TARGET PROTEIN OR POLYPEPTIDE BY USING POLYUBIQUITINATION | (주)프레이저테라퓨틱스 | 2023-06-22 | — | — | WO | disclosed |
| US-20080214801-A1 | CHEMOSELECTIVE LIGATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-09-04 | — | — | US | disclosed |
| US-20080181847-A1 | Targeted Imaging and/or Therapy Using the Staudinger Ligation | KONINKLIJKE PHILIPS ELECTRONICS, N.V. (NL) | 2008-07-31 | — | — | US | disclosed |
| US-20080181847-A1 | Targeted Imaging and/or Therapy Using the Staudinger Ligation | KONINKLIJKE PHILIPS ELECTRONICS, N.V. (NL) | 2008-07-31 | — | — | US | disclosed |
| US-20070037964-A1 | Condensation of a specifically engineered phosphine containing a cleavable linker so that a substituent of the phosphine is transferred to the azide, releasing an oxidized phosphine by-product and producing an amide bond in final product | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-02-15 | — | — | US | disclosed |
| US-20060276658-A1 | Chemoselective ligation | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2006-12-07 | — | — | US | disclosed |
| US-7122703-B2 | Chemoselective ligation | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-10-17 | — | — | US | disclosed |
| EP-1263771-B1 | CHEMOSELECTIVE LIGATION BY USE OF A PHOSPHINE | UNIV CALIFORNIA (US) | 2006-06-14 | — | — | EP | disclosed |
| US-20050148032-A1 | Chemoselective ligation | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2005-07-07 | — | — | US | disclosed |
| US-6570040-B2 | Condensation of specifically engineered phosphine which can provide for formation of amide bond between two reactive partners resulting in product comprising a phosphine moiety or which can be engineered to comprise a cleavable linker | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2003-05-27 | — | — | US | disclosed |
| US-20020016003-A1 | Chemoselective ligation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080181847-A1 | Targeted Imaging and/or Therapy Using the Staudinger Ligation | BTD, HLCS, BOLA2; BOLA2B | KDM4E 4551/4885ALDH1A1 1007/4885HPGD 2259/4885 |
| US-20020016003-A1 | Chemoselective ligation | PTMS, QPCT, DNPEP | KDM4E 2739/4885ALDH1A1 3286/4885HPGD 2792/4885 |
| US-20240199745-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | KDM4E 1013/4885ALDH1A1 1891/4885HPGD 3809/4885 |
| US-20250213685-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | KDM4E 1013/4885ALDH1A1 1891/4885HPGD 3809/4885 |
| US-20240425517-A1 | NOVEL COMPOUND FOR DEGRADATION OF TARGET PROTEIN OR POLYPEPTIDE BY POLYUBIQUITINATION | ADRM1, SUMO1, SUMO2 | KDM4E 2717/4885ALDH1A1 3989/4885HPGD 4414/4885 |
| US-20060276658-A1 | Chemoselective ligation | PTMS, PGF, ACSL3 | KDM4E 4071/4885ALDH1A1 2453/4885HPGD 3410/4885 |
| US-20070037964-A1 | Condensation of a specifically engineered phosphine containing a cleavable linker so that a substituent of the phosphine is transferred to the azide, releasing an oxidized phosphine by-product and producing an amide bond in final product | PTMS, PHOSPHO1, QPCT | KDM4E 3195/4885ALDH1A1 4060/4885HPGD 2529/4885 |
| US-20080214801-A1 | CHEMOSELECTIVE LIGATION | PTMS, QPCT, DNPEP | KDM4E 2739/4885ALDH1A1 3286/4885HPGD 2792/4885 |
| US-20050148032-A1 | Chemoselective ligation | PTMS, QPCT, DNPEP | KDM4E 2739/4885ALDH1A1 3286/4885HPGD 2792/4885 |
| US-20250177374-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | BCL2, BAX, BCL9 | KDM4E 1299/4885ALDH1A1 2826/4885HPGD 3359/4885 |
| US-20240058450-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | BCL2, BAX, BCL9 | KDM4E 1299/4885ALDH1A1 2826/4885HPGD 3359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.